Last checked at 12 Dec 2019 08:57
Grant of Share Options under Share Option Scheme
London: Thursday, December 12, 2019: Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) announces that on December 11, 2019, it granted share options under the Share Option Scheme conditionally adopted by Chi-Med at its Annual General Meeting in 2015 (the "2015 HCML Share Option Scheme").
Chi-Med granted 400,000 share options under its 2015 HCML Share Option Scheme to an employee to subscribe for Ordinary Shares subject to the acceptance of the grantee. Details of such share options granted prescribed are as follows:
Date of grant | : | December 11, 2019
|
Exercise price of share options granted | : | GBP3.592 per Ordinary Share
|
Number of share options granted | : | 400,000 (each share option shall entitle the holder thereof to subscribe for one Ordinary Share)
|
Closing market price of Ordinary Shares on the date of grant
| : | GBP3.400 per Ordinary Share
|
Validity period of the share options | : | From December 11, 2019 to December 10, 2029 |
About Chi-Med
Chi-Med (AIM/Nasdaq: HCM) is an innovative biopharmaceutical company which researches, develops, manufactures and markets pharmaceutical products. Its Innovation Platform, Hutchison MediPharma, has about 490 scientists and staff focusing on discovering, developing and commercializing targeted therapeutics and immunotherapies in oncology and autoimmune diseases. It has a portfolio of eight cancer drug candidates currently in clinical studies around the world. Chi-Med's Commercial Platform manufactures, markets, and distributes prescription drugs and consumer health products, covering an extensive network of hospitals across China.
Chi-Med is headquartered in Hong Kong and is dual-listed on the AIM market of the London Stock Exchange and the Nasdaq Global Select Market. For more information, please visit: www.chi-med.com.
Forward-Looking Statements
This announcement contains forward-looking statements within the meaning of the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements involve risks and uncertainties. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. For further discussion of these and other risks, see Chi-Med's filings with the U.S. Securities and Exchange Commission and on AIM. Chi-Med undertakes no obligation to update or revise the information contained in this announcement, whether as a result of new information, future events or circumstances or otherwise.
CONTACTS
Investor Enquiries |
| |
Mark Lee, Senior Vice President | +852 2121 8200 | |
Annie Cheng, Vice President | +1 (973) 567 3786 | |
David Dible, Citigate Dewe Rogerson | +44 7967 566 919 (Mobile) david.dible@citigatedewerogerson.com | |
Xuan Yang, Solebury Trout | +1 (415) 971 9412 (Mobile)xyang@troutgroup.com | |
Media Enquiries | ||
UK & Europe - Anthony Carlisle, Citigate Dewe Rogerson | +44 7973 611 888 (Mobile)anthony.carlisle@cdrconsultancy.co.uk | |
Americas - Brad Miles, Solebury Trout | +1 (917) 570 7340 (Mobile)bmiles@troutgroup.com | |
Hong Kong & Asia ex-China | - Joseph Chi Lo, Brunswick | +852 9850 5033 (Mobile)jlo@brunswickgroup.com |
- Zhou Yi, Brunswick | +852 9783 6894 (Mobile)yzhou@brunswickgroup.com | |
Mainland China - Sam Shen, Edelman | +86 136 7179 1029 (Mobile)sam.shen@edelman.com | |
Nominated Advisor | ||
Atholl Tweedie, Panmure Gordon (UK) Limited | +44 (20) 7886 2500 | |